| Literature DB >> 34615824 |
Mai Kikumoto1, Shuichiro Neshige1,2, Takeo Shishido1,2,3, Hiroki Ueno1,2,4, Shiro Aoki1, Koji Iida2,5, Hirofumi Maruyama1,2.
Abstract
We evaluated a 39-year-old pregnant woman with right temporal lobe epilepsy. During the second trimester, seizure deterioration was responsive to an increased daily dose of levetiracetam (LEV). However, immediately after delivery, new non-habitual seizures emerged along with a sharply increased LEV concentration. The frequency of habitual seizures also slightly increased. The non-habitual seizures completely disappeared, and the frequency of the habitual seizures improved to the baseline level after the LEV dosage was reduced. Thus, a paradoxical effect of an increased LEV blood concentration was assumed to be a potential cause of these events. Peripartum pharmacokinetic fluctuations in LEV levels should be monitored carefully.Entities:
Keywords: focal impaired awareness seizure; levetiracetam; pregnancy
Mesh:
Substances:
Year: 2021 PMID: 34615824 PMCID: PMC9107969 DOI: 10.2169/internalmedicine.8173-21
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.282
Figure 1.An interictal electroencephalogram (EEG) recorded before the pregnancy. Continuous repetitive spikes are visible in the right anterior to basal temporal regions every second during the drowsy state (yellow arrowheads).
Figure 2.Clinical course, including the peripartum period. The clinical courses of habitual seizures (FNMS and FIAS) and non-habitual seizures are illustrated. Bars indicate the frequency of each type of seizure, and the numbers in the bars indicate the frequency per month. The line graphs indicate changes in the body weight and blood concentration of the antiepileptic drugs during the peripartum period. Due to the long duration between the first and second examinations of the LEV blood concentration, the concentration changes during this period are shown by a red dashed line. FIAS: focal impaired awareness seizure, FNMS: focal aware non-motor seizure, LEV: levetiracetam, LCM: lacosamide